The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
Aims to achieve CDMO sales of US$ 400 million by 2028
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
A significant proportion of healthcare professionals still tend to favor branded drugs
Subscribe To Our Newsletter & Stay Updated
